alpha-aminopyridine has been researched along with Breast Neoplasms, Male in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agterof, M; Brown-Glaberman, U; Campone, M; Chatterjee, S; De Laurentiis, M; Kudryavcev, I; Martín, M; Menon-Singh, L; Palácová, M; Wu, J; Zamagni, C | 1 |
| Acar, Ö; Aksoy, S; Aykan, MB; Çelebi, A; Chalabiyev, E; Doğan, A; Dursun, B; Erdoğan, AP; Günenç, D; Güven, DC; Hacıbekiroğlu, İ; İnanç, M; Kahraman, S; Kaman, Ö; Keskinkılıç, M; Kılıçkap, S; Melisa Celayir, Ö; Mutlu, E; Ön, S; Özen, M; Vedat Bayoğlu, İ; Yalçın, Ş; Yavuzşen, T; Yıldırım, HÇ | 1 |
1 trial(s) available for alpha-aminopyridine and Breast Neoplasms, Male
| Article | Year |
|---|---|
Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Humans; Letrozole; Male; Neutropenia; Purines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2022 |
1 other study(ies) available for alpha-aminopyridine and Breast Neoplasms, Male
| Article | Year |
|---|---|
Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Female; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Receptor, ErbB-2 | 2022 |